Work

Survival benefits of concurrent immune checkpoint inhibitor and radiotherapy in non-small cell lung cancer with brain metastases

Year: 2025

Type: article

Abstract: BACKGROUND The optimal sequencing of immune checkpoint inhibitor (ICI) and brain radiotherapy in the management of brain metastasis from non-small cell lung cancer (NSCLC) is unclear. AIM To evaluate the survival of concurrent ICI and consolidation ICI in NSCLC patients treated with brain radiotherapy. METHODS We retrospectively analyzed NSCLC patients treated with brain radiotherapy and ICI. Treatment response and survival were estimated. The cox proportional hazards regression model was utilized to investigate the association between overall survival and clinical variables. RESULTS There were 54 patients in concurrent ICI and radiotherapy group, and 62 individuals treated with radiotherapy followed by consolidation ICI. The objective response rates were similar between the two group. The median progression free survival was significantly high in the concurrent ICI group compared with consolidation ICI group (9.56 months vs 8.15 months, P = 0.038). In addition, the median overall survival was 22.08 months in the concurrent ICI group, clearly longer than that in the consolidation group (13.24 months, P = 0.009). CONCLUSION In NSCLC patients with brain metastases, our analyses suggested that radiotherapy concurrent with ICI was associated with significant benefit compared with radiotherapy followed by consolidation ICI.

Source: World Journal of Clinical Oncology

DOI: 10.5306/wjco.v16.i8.107009

Authors: Xue-Jie Liu, Heng Ge, Chun-Luan Yuan

Institutions: The First People’s Hospital of Lianyungang, Fifth Affiliated Hospital of Zhengzhou University

Language: English

Topic: Brain Metastases and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funder: Pfizer